Skip to main content
Journal cover image

HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C.

Publication ,  Journal Article
Patel, K; Norris, S; Lebeck, L; Feng, A; Clare, M; Pianko, S; Portmann, B; Blatt, LM; Koziol, J; Conrad, A; McHutchison, JG
Published in: Hepatology
February 2006

Patients infected with HIV-1 who are heterozygous at HLA class I loci present greater variety of antigenic peptides to CD8+ cytotoxic T lymphocytes, slowing progression to AIDS. A similar broad immune response in chronic hepatitis C (CHC) infection could result in greater hepatic injury. Although specific HLA class II alleles may influence outcome in CHC patients, the role of HLA class I heterogeneity is generally less clearly defined. Our aims were to determine whether HLA class I allelic diversity is associated with disease severity and progression of fibrosis in CHC. The study population consisted of 670 adults with CHC, including 155 with advanced cirrhosis, and 237 non-HCV-infected controls. Serological testing for HLA class I antigens was performed via microlymphocytotoxicity assay. Peptide expression was defined as heterozygous (i.e., a different allele at each locus) or homozygous. Fibrosis staging was determined using METAVIR classification. Heterozygosity at the B locus (fibrosis progression rate [FPR] 0.08 vs. 0.06 units/yr; P = .04) and homozygosity at the A locus (FPR 0.10 vs. 0.08 units/yr; P = .04) predicted a higher median FPR. Age at infection, genotype, and duration of infection were also predictors of FPR. A higher proportion of patients with stage F2-F4 expressed HLA-B18 compared with controls (OR 2.2, 95% CI 1.17-4.23; P = .02). These differences were not observed in patients with advanced cirrhosis. HLA zygosity at 1, 2, or 3 alleles was not associated with fibrosis stage, liver inflammation, or treatment outcome. In conclusion, HLA class I allelic diversity has a minor influence on FPRs and disease severity in CHC.

Duke Scholars

Published In

Hepatology

DOI

ISSN

0270-9139

Publication Date

February 2006

Volume

43

Issue

2

Start / End Page

241 / 249

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Liver
  • Humans
  • Heterozygote
  • Hepatitis C, Chronic
  • Genetic Variation
  • Genes, MHC Class I
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, K., Norris, S., Lebeck, L., Feng, A., Clare, M., Pianko, S., … McHutchison, J. G. (2006). HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology, 43(2), 241–249. https://doi.org/10.1002/hep.21040
Patel, Keyur, Suzanne Norris, Lauralynn Lebeck, Anne Feng, Michael Clare, Stephen Pianko, Bernard Portmann, et al. “HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C.Hepatology 43, no. 2 (February 2006): 241–49. https://doi.org/10.1002/hep.21040.
Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology. 2006 Feb;43(2):241–9.
Patel, Keyur, et al. “HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C.Hepatology, vol. 43, no. 2, Feb. 2006, pp. 241–49. Pubmed, doi:10.1002/hep.21040.
Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, Portmann B, Blatt LM, Koziol J, Conrad A, McHutchison JG. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology. 2006 Feb;43(2):241–249.
Journal cover image

Published In

Hepatology

DOI

ISSN

0270-9139

Publication Date

February 2006

Volume

43

Issue

2

Start / End Page

241 / 249

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Liver
  • Humans
  • Heterozygote
  • Hepatitis C, Chronic
  • Genetic Variation
  • Genes, MHC Class I